You are here

  • Home
  • Online First
  • ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation

Article metrics

Article menu

other Versions

Download PDFPDF
Clinical trial
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation

 

Online download statistics by month:

Online download statistics by month: April 2022 to March 2023

AbstractFullPdf
Apr 202233763
May 202220162
Jun 2022576165
Jul 202227959
Aug 2022204117
Sep 202228221130
Oct 202226422234
Nov 202216912624
Dec 2022965920
Jan 2023705011
Feb 2023825918
Mar 202349359
Total2609806172